Top > Search of International Patents > CARTILAGE/BONE DESTRUCTION SUPPRESSOR

CARTILAGE/BONE DESTRUCTION SUPPRESSOR meetings

Foreign code F130007215
File No. S2011-1158-N0
Posted date Mar 14, 2013
Country WIPO
International application number 2012JP070872
International publication number WO 2013027658
Date of international filing Aug 10, 2012
Date of international publication Feb 28, 2013
Priority data
  • P2011-180899 (Aug 22, 2011) JP
Title CARTILAGE/BONE DESTRUCTION SUPPRESSOR meetings
Abstract The purpose of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of a cartilage or a bone occurring in rheumatoid arthritis, osteoarthritis, the bone metastasis of a malignant tumor and the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance.
Outline of related art and contending technology BACKGROUND ART
(Osteoarthritis(OA) ) is osteoarthritis, or aging due to mechanical stress, the decay of the surface of the articular cartilage, accompanying proliferation of new cartilage side edges of the joint, joint deformation, compatible in terms of the papermaking machine, and then proceeds to the further joint synovial inflammation is a disease. On the other hand, a typical arthritis in rheumatoid arthritis (rheumatoid arthritis (RA) ) in, and infection due to immune disorder, an inflammatory cells infiltrating the synovial membrane, further, angiogenesis in the synovial membrane with proliferation of the fibroblasts and when increased, inflammatory synovial granulation tissue is formed, destruction of the bone or cartilage proceeds, results in irreversible joint failure. For this reason, inflammatory disease rheumatoid arthritis (RA) whereas the called autoimmune diseases, osteoarthritis (OA) are referred to as a non-inflammatory diseases. Therefore, the therapeutic agent is used in the treatment of rheumatoid arthritis, osteoarthritis in a therapeutic effect is not thought to be general. Conventional, for the purpose of treating rheumatoid arthritis (RA) various pharmaceutical compositions have been developed. As one of the one of the 1 antibody and anti-Fas(patent document 1). However, anti-Fas antibody, rheumatoid arthritis (RA) of the synovial cells obtained from the patient but for apoptosis-inducing effect, of osteoarthritis (OA) synovial cells obtained from the patient to be ineffective for the induction of apoptosis have been reported (non-patent document 1). Current, osteoarthritis and rheumatoid arthritis joint as topical administration of adrenal cortical hormone and hyaluronic acid preparation is used, and the effect is temporary, the effects of these to inflammation and cartilage, constant for findings of the effect of suppressing bone destruction has not been obtained yet (non-patent document 2 and 3). In addition, various biologies (anti-TNF α antibody and the like) in the systemic administration of, cartilage inflammation RA, shown have an effect of suppressing bone destruction, systemic administration can also be treated by the resist (non-patent document 4) have arthritis. These organisms resistant to systemic administration of the formulation RA arthritis, further biological joint cartilage and performing a topical administration, the effect of suppressing bone destruction constant for not obtained findings of the (non-patent document 5). Far from the study of the inventors of the present invention, folate receptor (FR-β) β FR-β expression macrophages immunotoxins is at the center of the pathological condition of a disease or inhibit the inflammation can be easily estimated, administration of adrenal cortical hormone and hyaluronic acid as can be seen, the non-patent reference 6 as also discussed, cartilage is not necessarily an inflammation-suppressing, are not limited to suppress bone destruction. In fact, RA cartilage, bone destruction in an osteoclast differentiated from macrophages, macrophages produce cytokines such as TNF-α or IL-1, produced by macrophages and fibroblasts as a result of the metalloproteases and the like are considered to be complicatedly entangled (non-patent document 7-9). Patent Document 2 is, with respect to the folic acid receptor β toxin IgG-type antibody (Pseudomonas, exotoxin (Pseudomonas exotoxin) ) becomes bound to the synovial cells of rheumatoid arthritis patients to immunotoxins is cell death (apoptosis) induced is described, cartilage, bone destruction suppressing effect is not confirmed, osteoarthritis (OA) has not been discussed.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 葉酸リセプターβに対する抗体、又は該抗体と生物学的もしくは化学的活性物質との複合体を含有する軟骨又は骨の破壊抑制剤。

[請求項2]
 葉酸リセプターβに対する抗体が一重鎖又は二重鎖である請求項1記載の軟骨又は骨の破壊抑制剤。

[請求項3]
 生物学的もしくは化学的活性物質がトキシン、酵素、サイトカイン、アイソトープ及び化学療法剤から選ばれる少なくとも一つである請求項1又は2記載の軟骨又は骨の破壊抑制剤。

[請求項4]
 葉酸リセプターβ発現マクロファージが軟骨又は骨の破壊をおこす疾患を治療するための請求項1~3のいずれか1項に記載の軟骨又は骨の破壊抑制剤。

[請求項5]
 関節リウマチ、変形性関節症又は悪性腫瘍の骨転移による軟骨又は骨の破壊を抑制するための請求項1~3のいずれか1項に記載の軟骨又は骨の破壊抑制剤。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • MATSUYAMA, Takami
  • NAGAI, Taku
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close